Clinical Authority

PEMF for Chronic Pain:
The Evidence & the Authority.

36% pain reduction vs. 10% standard care. 55% medication reduction. The 2025 multicenter RCT, the mechanism, and the senior medical authorities standing behind the technology.

← Back to Articles
Physician discussing a chronic pain treatment plan with a patient in a clinic

Chronic pain — pain lasting more than three months — affects roughly one in five adults and is one of the most common reasons patients walk into a clinic. For a clinic operator, it represents a large, motivated, treatment-seeking population looking for a non-drug option. PEMF (Pulsed Electromagnetic Field) therapy has been studied as a component of multidisciplinary pain-management programs, and it is delivered in over 70 Israeli clinics serving a population of 9 million — now expanding to the Philippines.

What Is Chronic Pain, and How Does PEMF Help?

Chronic pain is pain that persists beyond three months, usually driven by ongoing inflammation, tissue damage, or sensitization of the nervous system. PEMF is a non-invasive, non-thermal therapy that delivers low-intensity magnetic pulses into tissue, triggering cellular processes that help reduce pain and inflammation. The treatment is painless, requires no needle or invasive contact, and is delivered while the patient rests. PEMF has been studied for chronic pain, fibromyalgia, inflammation reduction, and improving local blood flow.

The Medical Authority Behind the Technology

One of the strongest credibility signals for a clinic adopting PEMF is the seniority of the physicians and rehabilitation specialists associated with the technology. In Israel, the PainFree PEMF systems are backed by senior medical figures, including:

  • Prof. Itamar Grotto — former Associate Director-General of the Israeli Ministry of Health and head of Public Health Services.
  • Prof. Gabi Zeilig — Head of Rehabilitation at Sheba Medical Center, Tel HaShomer, who authored a comprehensive professional review recommending integration of the technology in clinics treating chronic pain.
  • Uria Moran — former Commander of the IDF Physiotherapy Corps.
  • Dr. Rafi Carasso — Head of Neurology at Hillel Yaffe Medical Center, who has used a PainFree PEMF system in his private practice for over 6 years.

PainFree is the long-established importer and integrator of advanced PEMF systems, with over 25 years of experience — the credibility base now being brought to Philippine clinics.

How PEMF Works — The Mechanism

PEMF acts at the cellular level. The magnetic pulses trigger a cascade of physiological processes that reduce pain and support tissue repair:

  1. Improved microcirculation — vasodilation and increased oxygen/nutrient delivery to tissue.
  2. Reduced inflammation — lower pro-inflammatory cytokines and local edema.
  3. Cellular activation — stimulation of mitochondrial ATP production and membrane-potential restoration.
  4. Tissue-repair support — promotion of angiogenesis and healing processes.
  5. Reduced pain-signal transmission — modulation of pain channels and reduced neural hypersensitivity.

Because chronic pain is typically characterized by persistent inflammation, impaired microcirculation, and nervous-system hypersensitivity, PEMF — shown to reduce edema and inflammation and to improve microcirculation — provides a direct clinical rationale. FDA-cleared PEMF devices are used worldwide as part of rehabilitation and pain-management programs.

What Does the Research Say?

  • Multicenter Randomized Controlled Trial — 2025 (PMC11914662, n=91, 5 orthopedic clinics): A prospective crossover trial of PEMF for joint and soft-tissue pain. Of 120 enrolled, 91 completed (48 PEMF, 43 standard care). Result: 36% pain reduction in the PEMF group vs. 10% standard care (p<0.0001), and a 55% reduction in medication use vs. 12%. The trial evaluated joint and soft-tissue pain broadly, not a single specific chronic-pain subtype.
  • Double-blind RCT in fibromyalgia — 2009 (PubMed 19920724, n=56): Sham-controlled trial in 56 women, two daily 30-minute sessions for three weeks. Significant improvement in FIQ, VAS pain, BDI, and SF-36, sustained at 12-week follow-up — supporting evidence for widespread chronic pain.
  • Clinical review — Strauch et al., 2009, Aesthetic Surgery Journal (PubMed 19371845, Albert Einstein): Documents that PEMF relieves pain and edema, accelerates wound healing, and promotes angiogenesis — a mechanistic basis for soft-tissue pain.

The evidence base varies by indication: research supports PEMF as part of a combined treatment plan, particularly in musculoskeletal and soft-tissue pain, rather than as a stand-alone cure.

PEMF vs. Conventional Chronic-Pain Treatments

Parameter PEMF (PainFree) NSAIDs / Medication Corticosteroid Injections Physiotherapy
Is it invasive? Non-invasive, no needle Non-invasive (oral) Invasive — injection Non-invasive
Effect over time Cumulative, lasting Temporary symptom relief Temporary in some cases Gradual, sustained
Repeatable? Unlimited repeat series Prolonged use raises risk Limited (~3–4/year per site) Unlimited
Risk / side effects Very low, no tissue damage GI and kidney burden Tendon/cartilage weakening with repeats Low, load-dependent
Painful during treatment? Painless, comfortable Painless to take Injection can hurt Controlled discomfort
Therapist working time 0 minutes (Hands-Free) Short prescription Requires an injecting physician Full session
Research evidence 2025 RCT, n=91, −36% pain Extensive, symptomatic Short-term efficacy Extensive, adherence-dependent

Every technology has its place depending on the clinical situation and treatment goal. In many cases, combining PEMF with physiotherapy, shockwave (ESWT), or controlled medication amplifies results — so the choice is not necessarily "either/or."

What This Means for a Philippine Clinic

For a clinic operator, PEMF adds a premium treatment layer that runs in parallel with the therapist's work. The treatment requires no supervision — so, first and foremost, it enables better clinical outcomes per the research, while also letting the clinic serve additional patients at the same time. At roughly ₱1,500–2,500 per session across a typical multi-session course, chronic-pain patients are a high-value, motivated segment: they have often already failed other treatments and complete full treatment courses.

Contraindications & Safety

PEMF has an excellent safety record with over 40 years of clinical use. Contraindications are narrow: active pacemaker or electronic implant, pregnancy, active epilepsy (consult a neurologist), and active malignancy. Most of the population — including athletes and children of all ages — can receive treatment.

Interested in adding PEMF to your clinic?

Request the full investment brief — machine specs, financials, and site selection for the Philippines market.

Request Investment Brief →